MyBlueDots

NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today highlighted its 2024 accomplishments and announced its anticipated key milestones for 2025. “With our team’s innovation and execution throughout 2024, Rallybio is well positioned to create meaningful value in 2025,” said Stephen Uden, M.D., Chief Executive Officer of Rallybi

MIAMI–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the appointment of Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer. “We are thrilled to have Paul assume the role of Chief Executive Officer,” said Pulse Biosciences’ Co-Chairman of the Board Robert W. Duggan. “Having worked very clo

JERSEY CITY, N.J.–(BUSINESS WIRE)–Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health company, to develop innovative treatments for patients with age-related macular degeneration (AMD). This relationship, initiated in 2024, represents a major step forward by bringing together Bausch + Lomb’s extensive expertise in ophthalmology with Character Bio’s integrated patient data platform a

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Terremoto Biosciences, a biotechnology company developing first- and best-in-class targeted therapeutics, today announced the appointment of James Christensen, Ph.D., as President and Head of Research & Development. “The most important predicter of successful drug development is a team of people who have successfully developed a therapy from discovery to regulatory approval,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto.

SAN DIEGO–(BUSINESS WIRE)—- $ARCT #ClinicalTrial–Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the initiation of the Company’s Phase 1 study of ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H

BASEL, Switzerland & PHILADELPHIA–(BUSINESS WIRE)–RhyGaze, a biotechnology company based in Basel, Switzerland and Philadelphia, Pa., USA, today announced that it has secured a Series A financing of USD 86 million. The round was led by GV (Google Ventures), alongside Arch Venture Partners, F-Prime Capital and founding investors BioGeneration Ventures and Novartis Venture Fund, who contributed USD 11 million to an earlier seed round. RhyGaze was founded on intellectual property exclusively lic

WALTHAM, Mass.–(BUSINESS WIRE)–Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the expanded commercial availability of the NavDx test for Molecular Residual Disease (MRD) detection in anal squamous cell carcinoma (ASCC) patients. NavDx, Naveris’ proprietary flagship blood test, is the first and only clinically validated circulating tumor TTMV®-HPV DNA blood test that provides a non-invasive and precise method that can detect MRD before th

BOULDER, Colo.–(BUSINESS WIRE)–Enveda, a biotechnology company using AI to translate life’s chemistry into new medicines, today announced the appointment of Jason Kim as Chief Financial Officer (CFO). Mr. Kim brings more than 20 years of biopharmaceutical corporate development and financial leadership experience to the Enveda team. In his new role, Mr. Kim will oversee Enveda’s financial strategy and operations, contributing to the company’s growth as it continues to develop innovative therap

MORRISVILLE, N.C.–(BUSINESS WIRE)–Arrivo BioVentures today announced positive data from its SP-624-103 study evaluating the impact of SP-624’s novel epigenetic mechanism of action on neurological pathways. The findings provide insights into the potential antidepressant and cognitive effects of SP-624, a SIRT6 activator that may be the first treatment specifically for females with Major Depression based on previous studies. Arrivo’s SP-624-103 study is a double blind, placebo-controlled study

SHANGHAI & CAMBRIDGE, Mass. & BOSTON–(BUSINESS WIRE)–Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and